The aim of this project is to define the effects of blocking E2A-PBX1 expression in a leukemia cell line containing the E2A-PBX1 translocation. Specifically we propose to study the effects of E2A-PBX1siRNA on growth and viability (aim 1) and whole genome gene expression (aim 2). Lastly, genes identified as having altered expression by siRNA will be compared to the previously published expression profile of E2A-PBX1 containing leukemias (aim 3).
The ALSF Infrastructure funding will help support the second phase of the Clinical Research Office growth at Nationwide Children's Hospital. Led by Sarah O'Brien, MD And Timothy Cripe, MD, PhD, the second phase of growth includes the successful launching of investigator-initiated and early phase protocol to the kids being treated at Nationwide.
Due to advances in research and treatment there is a growing population of childhood cancer survivors. While the survival rate is a very positive growing trend, it is important for survivors to monitor their health on an ongoing bases as a majority of the survivors will develop at least one long-term side effect from treatment. The incidence of late effects increases with age and often are not clinically apparent until decades after cancer treatment. The need for continuity and blending of oncology and primary care is imperative.
Osteosarcoma is the most common malignant bone tumor in kids. Osteosarcoma frequently express constantly activated STAT3, which is required for cancer progression. Therefore, the development of STAT3 inhibitors for osteosarcoma therapy is desirable and should have high clinical impact. We have developed a novel STAT3 drug discovery approach using multiple ligand simultaneous docking (MLSD) and drug repositioning. MLSD can check multiple fragments from existing drugs already approved for use in humans for docking to STAT3 binding sites.
Chris loves baseball – he has a history of playing for his high school team and is a longtime fan of the San Francisco Giants. However, when he was in high school, Chris began having strange symptoms. Today, Chris is a three-time survivor of glioblastoma.
